Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Chemical & Pharmaceutical Bulletin|September 19, 2002
Removal of fine powders from film surface. II. Effect of operating parameters on the removal efficiencySatoru Watano, Takumi Okamoto, Teruo Suzuki
Chemical & Pharmaceutical Bulletin|April 4, 2022
Isolation of Natural Prodrug-Like Metabolite by Simulating Human Prodrug Activation in Filamentous FungusTakumi Okamoto, Shinji Kishimoto, Kenji Watanabe
International Journal of Clinical Pharmacology and Therapeutics|November 11, 2022
Inverse association between DPP-4 inhibitor use and fracture in older adults: A disproportionality analysis of the FAERS and JADERKatsuhiro Ohyama, Takumi Okamoto, Yusuke Hori
International Journal of Molecular Sciences|June 4, 2020
The Role of Tissue-Specific Ubiquitin Ligases, RNF183, RNF186, RNF182 and RNF152, in Disease and Biological FunctionTakumi Okamoto, Kazunori Imaizumi, Masayuki Kaneko
Chemical & Pharmaceutical Bulletin|October 7, 2004
Determination of optimal formulation for extrusion granulation by compression test of wet kneaded massYoshito Ohnishi, Takumi Okamoto, Satoru Watano
Chemical & Pharmaceutical Bulletin|December 6, 2005
Scale-up of high shear granulation based on agitation powerYoshinobu Sato, Takumi Okamoto, Satoru Watano
Chemical & Pharmaceutical Bulletin|April 2, 2005
Scale-up of high shear granulation based on the internal stress measurementSatoru Watano, Takumi Okamoto, Yoshinobu Sato, et al.
Journal of the American Chemical Society|March 18, 2025
Enantioselective Biosynthesis of (+)- and (-)-AuranthinesShinji Kishimoto, Tsubasa Tamura, Takumi Okamoto, et al.
Scientific Reports|July 27, 2016
Translocation of the ABC transporter ABCD4 from the endoplasmic reticulum to lysosomes requires the escort protein LMBD1Kosuke Kawaguchi, Takumi Okamoto, Masashi Morita, et al.
International Journal of Clinical Pharmacology and Therapeutics|October 22, 2025
Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting SystemKatsuhiro Ohyama, Nonoka Abe, Takumi Okamoto, et al.
Pageof 4